Transparency, Repricing, and Price Convergence in Cancer Care.

Forrest Xiao¹, Lily Boe², Dan Snow¹, Matthew Dimaano³, David Rubin³, Jonas Nelson⁴, Babak J Mehrara⁴, Evan Matros⁴, Danielle H Rochlin⁵

¹Quantitative Research Group, Turquoise Health, San Diego, CA, USA.

²Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

³Health Outcomes and Quantitative Analytics, Department of Finance, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

⁴Plastic and Reconstructive Surgery Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

⁵Plastic and Reconstructive Surgery Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address: rochlind@mskcc.org.

PubMed DOI

Abstract

OBJECTIVES: Cancer imposes a significant economic burden on the US healthcare system and its patients. We quantified changes in price levels and variation for oncologic services after federal price transparency regulations and evaluated whether the prevalence and granularity of disclosures were associated with these changes. METHODS: This retrospective longitudinal study used nationwide hospital…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.